- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01683188
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma (PROCLIVITY01)
A Multi-Center Study of High Dose Aldesleukin (Interleukin-2) + Vemurafenib Therapy in Patients With BRAFV600 Mutation Positive Metastatic Melanoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This will be an open-label, uncontrolled two-arm, multi-center study in patients with metastatic melanoma with BRAFV600 oncogene mutations. Patients will initially receive treatment with vemurafenib interspersed with two courses of High Dose IL-2 (HD IL-2). Patients are eligible for the study if they have melanoma positive for the BRAFV600 mutation, have been on vemurafenib therapy for 0-18 weeks, have responding or stable disease if on vemurafenib, and meet the requirements for dosing with HD IL-2 and all protocol inclusion and exclusion criteria.
Two Cohorts will be enrolled, differing only in how they are characterized prior to HD IL-2 treatment:
Cohort 1: will consist of 135 patients naïve to vemurafenib and HD IL-2 therapy. Patients in Cohort 1 will have an initial evaluation and receive a defined 6 (± 1) week course of vemurafenib before beginning HD IL-2. This Cohort will be used to define study size and statistical validity with the comparator being historic controls (using data from the BRAF positive patients from the Melanoma SELECT study Protocol IIT10PLK06).
Cohort 2: will consist of up to 50 patients who have been on vemurafenib therapy for >7 to 18 weeks with stable or responding disease before starting HD IL-2. Patients in Cohort 2 will have an initial evaluation and will begin HD IL-2 treatment after >7 to 18 weeks of treatment with vemurafenib. This Cohort is designed to evaluate whether additive or synergistic clinical benefit or toxicity is observed in BRAFV600 mutation positive metastatic melanoma patients treated with vemurafenib as a single agent for >7 to18 weeks prior to the first course of HD IL-2 therapy in conjunction with continued vemurafenib.
Patients in both cohorts will discontinue dosing vemurafenib prior to each treatment with HD IL-2 and resume dosing after each discharge. Patients will receive up to two courses (four cycles) of HD IL-2 and will be evaluated for their disease responses at 10 weeks (±3 weeks) from the start of HD IL-2 dosing, and 26 weeks (±3 weeks) from the start of HD IL-2 dosing. QTc intervals will be reviewed daily for changes during each cycle of HD IL-2 dosing.
Administration of vemurafenib and HD IL-2 will be according to the respective Package Inserts and according to the Institution's standard of care. The investigator will determine the number of HD IL-2 cycles each patient will receive, according to the investigator's discretion and medical judgment.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Arizona
-
Tucson, Arizona, United States, 85719
- University Arizona Cancer Center
-
-
California
-
La Jolla, California, United States, 92093
- Moores UCSD Cancer Center
-
-
Florida
-
Miami Beach, Florida, United States, 33140
- MSMC Research Program
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University School of Medicine
-
-
Illinois
-
Maywood, Illinois, United States, 60153
- Loyola University Medical Center, Div of Hematology/Oncology
-
Park Ridge, Illinois, United States, 60068
- Luther General Cancer Care Institute
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa Hospitals and Clinics
-
-
Kansas
-
Kansas City, Kansas, United States, 66160-0003
- University of Kansas
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70809
- Hematology/Oncology Clinic
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan, Comprehensive Cancer Center
-
Detroit, Michigan, United States, 48201
- Karmanos Cancer Institute
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota Masonic Cancer Center
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03756
- Dartmouth-Hitchcock Medical Center
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- John Theurer Cancer Center at Hackensack University Medical Center
-
-
New York
-
New York, New York, United States, 10032
- Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- The Christ Hospital Cancer Center
-
Cleveland, Ohio, United States, 44106
- Case Comprehensive Cancer Center
-
-
Oregon
-
Portland, Oregon, United States, 97213
- Providence Cancer Center
-
-
Pennsylvania
-
Easton, Pennsylvania, United States, 18045
- St. Luke's Hospital, Anderson Campus
-
Pittsburgh, Pennsylvania, United States, 15232
- UPMC Cancer Centers
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female patients 18 years of age or older.
- Confirmed and measurable metastatic melanoma with the BRAFV600 mutation.
- Patients with at least one metastatic melanoma lesion accessible. for biopsy prior to vemurafenib treatment if no archived tissue is available.
- Meet the requirements for HD IL-2 therapy per institutional guidelines.
- Meet the requirements for vemurafenib therapy per institutional guidelines.
- Patient must be willing to provide written Informed Consent and participate in study procedures as described in the 12PLK01. Patients consented for 12PLK01 will also be asked to participate in the 10PLK13 PROCLAIM (Proleukin®) registry study.
Exclusion Criteria:
- A patient will not be considered eligible for study participation if any of the following exclusion criteria are met:
Prior therapy of metastatic disease with any of the following: IL-2, Ipilimumab, or other highly selective BRAF, MEK, NRAS, cMET inhibitors (e.g. GSK2118436 or GSK1120212) and TKIs.
Exception: with a 6 week washout the following are allowed:
- Adjuvant Ipilimumab,
- Anti PD-1, Anti PD L-1
- Exclusion for Cohort 1 only: vemurafenib treatment >7 weeks.
- Exclusion for Cohort 2 only: vemurafenib treatment <7 weeks. (eligible for Cohort 1) or >18 weeks.
- QTc interval of >500ms.
- Patients with known or suspected infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV) or other infectious hepatitis.
- Pregnant, nursing or planning to become pregnant.
- Untreated brain metastases. (Brain metastases that have been treated, which no longer require corticosteroid therapy and are without progression by MRI assessment at least 6 weeks after definitive therapy are acceptable.)
- Received investigational drug within 30 days prior to study dosing. Patients may participate in non-interventional or observational clinical study (ies)
- Concomitant disease or condition that would interfere with the conduct of the study or that would, in the opinion of the Investigator, pose an unacceptable risk to the patient in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: Cohort 1
Patients who have received less than 7 weeks vemurafenib dosing prior to treatment with HD IL-2
|
Other Names:
|
OTHER: Cohort 2
Patients who have receive >7 weeks to 18 weeks vemurafenib dosing prior to treatment with HD IL-2
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess Complete Response (CR) rate in BRAFV600 mutation positive metastatic melanoma patients who have received vemurafenib plus HD IL-2 at 10 (±3) weeks from the start of HD IL-2 dosing to assess initial response and 26 (±3) weeks to assess and change
Time Frame: 10 weeks, 26 weeks
|
assessment of tumor response in patients with CR or near CR (> 90%) after discontinuation of vemurafenib, based on RECIST criteria
|
10 weeks, 26 weeks
|
compare safety between patients treated with vemurafenib and HD IL-2 versus historical HD IL-2 alone
Time Frame: through study completion, an average of 1 year
|
incidence of adverse events
|
through study completion, an average of 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Compare PFS
Time Frame: 1 year
|
compare progression free survival (PFS) from initiation of vemurafenib between Cohort 1 and Cohort 2 patients, compare overall PFS with the historical data using vemurafenib or HD IL-2 alone,
|
1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Tharak Rao, MD, Prometheus Laboratories
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 12PLK01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Melanoma
-
Mohammed M MilhemGenentech, Inc.TerminatedMelanoma | Metastatic Melanoma | BRAF-mutated Metastatic Melanoma | V600EBRAF-mutated Metastatic MelanomaUnited States
-
Delcath Systems Inc.Active, not recruitingMetastatic Uveal Melanoma | Metastatic Ocular MelanomaUnited States
-
National Cancer Institute (NCI)TerminatedMetastatic Uveal Melanoma | Metastatic Ocular MelanomaUnited States
-
MorphotekTerminatedMelanoma | Metastatic Melanoma | Advanced Melanoma | Malignant Metastatic MelanomaUnited States
-
GlaxoSmithKlineWithdrawnCancer | Metastatic Uveal Melanoma | GNA11 Mutation-positive Metastatic Melanoma | GNAQ Mutation-positive Metastatic Melanoma
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingMetastatic Melanoma | Metastatic Uveal Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage III Cutaneous... and other conditionsUnited States
-
Elizabeth DavisBristol-Myers SquibbTerminatedMetastatic Melanoma | Advanced Melanoma | Metastatic Melanoma Stratified by MHC-II ExpressionUnited States
-
Fred Hutchinson Cancer CenterAmazon.com Services LLCRecruitingAnatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC... and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Cutaneous Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Recurrent Cutaneous Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Recurrent Mucosal Melanoma | Metastatic Mucosal Melanoma | Non-Cutaneous Melanoma | Metastatic Non-Cutaneous Melanoma | Recurrent Non-Cutaneous...United States, Canada, Ireland
-
Provectus Biopharmaceuticals, Inc.Active, not recruitingMetastatic Colorectal Cancer | Hepatocellular Carcinoma | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Melanoma | Metastatic Uveal Melanoma | Metastatic Pancreatic Cancer | Metastatic Colon Cancer | Metastatic Ocular Melanoma | Cancer Metastatic to the LiverUnited States
Clinical Trials on vemurafenib + HD IL-2
-
Ariel UniversityTel Aviv UniversityCompleted
-
University of MichiganNational Institute on Aging (NIA)RecruitingMild Cognitive Impairment | Dementia of Alzheimer TypeUnited States
-
Peking University Third HospitalRecruitingAmyotrophic Lateral SclerosisChina
-
Brigham and Women's HospitalTerminatedAbdominal Wall Defect | Amputation, Traumatic | Amputation;Traumatic;Old | Face Injury | Face; DeformityUnited States
-
Peking University People's HospitalUnknown
-
jiangjingtingUnknownLymphoma, B CellChina
-
University of ChicagoTerminatedMetastatic Renal Cell CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedMelanoma | Neoplasm MetastasisUnited States
-
National Cancer Institute (NCI)CompletedNon Hodgkin's Lymphoma | Hodgkin's DiseaseUnited States
-
University of MinnesotaCompleted